Product
Meropenem
Aliases
Meropenem for Injection, Merrem
24 clinical trials
26 indications
Indication
Urinary Tract InfectionsIndication
PyelonephritisIndication
Mental Health IssueIndication
Complicated UTIIndication
Healthy Control ParticipantsIndication
Bacterial InfectionsIndication
Complicated Intra-Abdominal InfectionIndication
complicated intra-abdominal infectionsIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
ARDSIndication
Septic shockIndication
Enterobacteriaceae InfectionsIndication
BacteremiaIndication
InfectionIndication
Kidney FailureIndication
Febrile NeutropeniaIndication
Carbapenem Resistant Bacterial InfectionIndication
Acinetobacter baumannii BacteremiaIndication
Acinetobacter PneumoniaIndication
TuberculosisIndication
PulmonaryIndication
bloodstream infectionsIndication
SepsisClinical trial
A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute PyelonephritisStatus: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Multicenter, Randomized, Open, Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Colistimethate Sodium for Injection in the Treatment of Carbapenem Resistant Gram-negative Infections in Chinese Adults.Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in AdultsStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of Intravenous ANT3310 Alone and in Combination With Meropenem in Healthy SubjectsStatus: Completed, Estimated PCD: 2024-01-05
Clinical trial
A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in AdultsStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-10-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including PyelonephritisStatus: Completed, Estimated PCD: 2020-12-03
Clinical trial
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal InfectionStatus: Completed, Estimated PCD: 2020-03-16
Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal InfectionStatus: Completed, Estimated PCD: 2020-10-14
Clinical trial
An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Study To Determine The Impact Of Serial Procalcitonin On Improving Antimicrobial Stewardship And On The Efficacy, Safety, And Tolerability Of Imipenem-Cilastatin-Relebactam Plus/Minus Vancomycin Or Linezolid Versus Standard Of Care Antipseudomonal Beta-Lactams Plus/Minus Vancomycin Or Linezolid As Empiric Therapy In Febrile Neutropenic Adults With CancerStatus: Completed, Estimated PCD: 2023-10-06
Clinical trial
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged VentilationStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged VentilationStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Pharmacokinetics of Meropenem During High-dose Continuous Renal Replacement Therapy in Critically Ill PatientsStatus: Completed, Estimated PCD: 2018-12-31
Clinical trial
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized TrialStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
PipEracillin/Tazobactam vs mERoPENem for Treatment of AmpC-producing Bloodstream Infections: an Extension of the Original PETERPEN TrialStatus: , Estimated PCD: 2028-04-15
Clinical trial
Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 2a Study of the Early Bactericidal Activity of Rifampin (RIF) in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampin-resistant or Rifampin-susceptible Pulmonary TuberculosisStatus: Completed, Estimated PCD: 2022-05-13
Clinical trial
Randomised Controlled Trial of Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Due to Enterobacteriaceae Showing Resistance to Third Generation CephalosporinsStatus: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low-risk PatientsStatus: Completed, Estimated PCD: 2020-12-31
Clinical trial
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) TrialStatus: Not yet recruiting, Estimated PCD: 2028-06-30
Clinical trial
Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care UnitStatus: Recruiting, Estimated PCD: 2026-04-01